Close

Search

Subscribe
Browse Category

Phase 1

2 Articles
RC148 bispecific antibody simultaneously targeting PD-1 and VEGF as immune cells attack squamous and non-squamous lung tumors.

RemeGen and AbbVie’s RC148 Delivers 90% Response Rate in a Phase 1b Trial of First-Line Squamous NSCLC

By Chris Chen
No Comments on RemeGen and AbbVie’s RC148 Delivers 90% Response Rate in a Phase 1b Trial of First-Line Squamous NSCLC
5 Min Read

The PD-1/VEGF bispecific antibody produced high response rates with chemotherapy across squamous and non-squamous lung cancer cohorts, supporting its advancement into Phase 3 development. RemeGen and AbbVie have reported strong early clinical results for…

Illustration of iza-bren above EGFR and HER3 receptors on a lung cancer cell, with labeled targets and golden drug payloads.

Biokin’s Iza-Bren Shows Activity in Previously Treated EGFR-Mutated Lung Cancer, Supports Global Registrational Dose

By Chris Chen
No Comments on Biokin’s Iza-Bren Shows Activity in Previously Treated EGFR-Mutated Lung Cancer, Supports Global Registrational Dose
4 Min Read

Biokin’s U.S. subsidiary SystImmune has reported new global Phase 1 results for iza-bren, its EGFR×HER3 bispecific antibody-drug conjugate (ADC), supporting selection of a dose for registrational testing in patients with previously treated EGFR-mutated…